CSL Behring is a global biotherapeutics leader driven by its promise to save lives. It is our mission to discover, develop, and deliver innovative therapies that improve patients' quality of life. Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies and other rare and serious diseases. In Switzerland, CSL Behring has two manufacturing sites. In the capital city Bern and in Lengnau BE. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries.
Products, services, technology
Biotherapies treating rare diseases such as von Willebrand disease (VWD), hemophilia, primary immunodeficiency (PID), hereditary angioedema (HAE), or Alpha-1 antitrypsin deficiency, and biotherapies to prevent hemolytic disease of the newborn, and prevent/stop bleeding in emergencies/planned surgery.
Our partnering approach is to structure deals that leverage the value of our R&D, commercial and manufacturing operations. We partner with industry leaders, academia, governments and scientific organizations to contribute our know-how and technologies to bring innovative medicines to life.